Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241337 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL243805 | 0.96 | ADORA2A (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL240082 | 0.90 | ADORA2A (0.51) | ADORA2AADORA3ADORA1 | |
| SCHEMBL243244 | 0.88 | ADORA2A (0.52) | ADORA2AADORA3ADORA1 | |
| SCHEMBL243451 | 0.87 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL243007 | 0.86 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL242165 | 0.86 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL241191 | 0.86 | ADORA2A (0.46) | ADORA2AADORA3ADORA1 | |
| SCHEMBL242164 | 0.86 | ADORA2A (0.49) | ADORA2AADORA3ADORA1 | |
| SCHEMBL2992504 | 0.84 | ADORA2A (0.54) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |